Do analysts prefer GOVX or SQZ?

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 22,800.76%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than SQZ Biotechnologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to GOVX or SQZ?

In the previous week, GeoVax Labs had 4 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 5 mentions for GeoVax Labs and 1 mentions for SQZ Biotechnologies. GeoVax Labs' average media sentiment score of 0.57 beat SQZ Biotechnologies' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SQZ Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BIAF or SQZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor BIAF or SQZ?

In the previous week, bioAffinity Technologies had 6 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 7 mentions for bioAffinity Technologies and 1 mentions for SQZ Biotechnologies. bioAffinity Technologies' average media sentiment score of 0.36 beat SQZ Biotechnologies' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SQZ Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SQZ or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 752.27%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than SQZ Biotechnologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend PPCB or SQZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor PPCB or SQZ?

In the previous week, Propanc Biopharma had 3 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 4 mentions for Propanc Biopharma and 1 mentions for SQZ Biotechnologies. Propanc Biopharma's average media sentiment score of 0.72 beat SQZ Biotechnologies' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SQZ Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SQZ or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SQZ or GNPX more profitable?

Genprex has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96% -119.83% -59.90% Genprex N/A -192.88% -145.45%

SQZ Biotechnologies (SQZ) Competitors

$0.02 0.00 (0.00%)

As of 08/14/2026

Compare

SQZ vs. GOVX, BIAF, DCOY, PPCB, and GNPX

Should you buy SQZ Biotechnologies stock or one of its competitors? SQZ Biotechnologies's main competitors and comparable companies include GeoVax Labs (GOVX), bioAffinity Technologies (BIAF), Decoy Therapeutics (DCOY), Propanc Biopharma (PPCB), and Genprex (GNPX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SQZ Biotechnologies compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GeoVax Labs has higher earnings, but lower revenue than SQZ Biotechnologies. GeoVax Labs is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.91	-$21.47M	-$11.34	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 22,800.76%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than SQZ Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GeoVax Labs has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

GeoVax Labs has a beta of 3.73, meaning that its stock price is 273% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

In the previous week, GeoVax Labs had 4 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 5 mentions for GeoVax Labs and 1 mentions for SQZ Biotechnologies. GeoVax Labs' average media sentiment score of 0.57 beat SQZ Biotechnologies' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SQZ Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GeoVax Labs beats SQZ Biotechnologies on 8 of the 15 factors compared between the two stocks.

How does SQZ Biotechnologies compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

bioAffinity Technologies has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

bioAffinity Technologies has higher earnings, but lower revenue than SQZ Biotechnologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.52	-$14.91M	-$7.30	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

bioAffinity Technologies has a net margin of -257.30% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

In the previous week, bioAffinity Technologies had 6 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 7 mentions for bioAffinity Technologies and 1 mentions for SQZ Biotechnologies. bioAffinity Technologies' average media sentiment score of 0.36 beat SQZ Biotechnologies' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SQZ Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

SQZ Biotechnologies beats bioAffinity Technologies on 8 of the 14 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Decoy Therapeutics?

SQZ Biotechnologies (NYSE:SQZ) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Decoy Therapeutics has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
Decoy Therapeutics	N/A	-315.22%	-167.15%

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 752.27%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than SQZ Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

In the previous week, Decoy Therapeutics had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 2 mentions for Decoy Therapeutics and 1 mentions for SQZ Biotechnologies. Decoy Therapeutics' average media sentiment score of 1.47 beat SQZ Biotechnologies' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
SQZ Biotechnologies	Neutral
Decoy Therapeutics	Positive

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Comparatively, 1.5% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Decoy Therapeutics has lower revenue, but higher earnings than SQZ Biotechnologies. Decoy Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Summary

SQZ Biotechnologies beats Decoy Therapeutics on 8 of the 15 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Propanc Biopharma has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

38.5% of SQZ Biotechnologies shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Propanc Biopharma has higher earnings, but lower revenue than SQZ Biotechnologies. Propanc Biopharma is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

In the previous week, Propanc Biopharma had 3 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 4 mentions for Propanc Biopharma and 1 mentions for SQZ Biotechnologies. Propanc Biopharma's average media sentiment score of 0.72 beat SQZ Biotechnologies' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SQZ Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

Summary

Propanc Biopharma beats SQZ Biotechnologies on 7 of the 13 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Genprex?

SQZ Biotechnologies (NYSE:SQZ) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
Genprex	N/A	-192.88%	-145.45%

Genprex has lower revenue, but higher earnings than SQZ Biotechnologies. Genprex is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A

SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market. Comparatively, Genprex has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market.

In the previous week, Genprex had 2 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 3 mentions for Genprex and 1 mentions for SQZ Biotechnologies. Genprex's average media sentiment score of 1.42 beat SQZ Biotechnologies' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
SQZ Biotechnologies	Neutral
Genprex	Positive

Summary

SQZ Biotechnologies beats Genprex on 8 of the 13 factors compared between the two stocks.

Get SQZ Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SQZ vs. The Competition

Export

Metric	SQZ Biotechnologies	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$708K	$3.74B	$7.03B	$24.35B
Dividend Yield	N/A	3.69%	2.56%	3.69%
P/E Ratio	-0.01	11.49	270.85	30.51
Price / Sales	0.04	1,270.39	597.39	20.97
Price / Cash	N/A	45.11	28.87	20.48
Price / Book	0.01	17.17	11.09	4.92
Net Income	-$79.46M	-$13.18M	$3.45B	$1.07B
7 Day Performance	N/A	1.53%	0.74%	0.25%
1 Month Performance	N/A	2.99%	2.15%	2.59%
1 Year Performance	N/A	56.69%	63.00%	18.80%

SQZ Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SQZ SQZ Biotechnologies	N/A	$0.02 flat	N/A	N/A	$708K	$18.16M	N/A	1,620
GOVX GeoVax Labs	3.1329 of 5 stars	$0.74 -2.7%	$150.00 +20,121.1%	-96.2%	$2.65M	$2.49M	N/A	10	Short Interest Decrease Gap Up
BIAF bioAffinity Technologies	0.5973 of 5 stars	$0.53 -3.7%	N/A	-94.2%	$2.61M	$6.16M	N/A	10	Upcoming Earnings Short Interest Decrease
DCOY Decoy Therapeutics	2.1769 of 5 stars	$4.19 -4.1%	$30.00 +616.0%	N/A	$2.58M	N/A	N/A	20	Earnings Report Gap Down
PPCB Propanc Biopharma	0.9811 of 5 stars	$1.18 +15.7%	N/A	-98.3%	$2.32M	N/A	N/A	1	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SQZ) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SQZ Biotechnologies (SQZ) Competitors

SQZ vs. GOVX, BIAF, DCOY, PPCB, and GNPX

How does SQZ Biotechnologies compare to GeoVax Labs?

Summary

How does SQZ Biotechnologies compare to bioAffinity Technologies?

Summary

How does SQZ Biotechnologies compare to Decoy Therapeutics?

Summary

How does SQZ Biotechnologies compare to Propanc Biopharma?

Summary

How does SQZ Biotechnologies compare to Genprex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SQZ vs. The Competition

SQZ Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SQZ Biotechnologies (SQZ) Competitors

SQZ vs. GOVX, BIAF, DCOY, PPCB, and GNPX

How does SQZ Biotechnologies compare to GeoVax Labs?

Do insiders and institutionals believe in GOVX or SQZ?

Which has better earnings and valuation, GOVX or SQZ?

Do analysts prefer GOVX or SQZ?

Is GOVX or SQZ more profitable?

Which has more volatility & risk, GOVX or SQZ?

Does the media refer more to GOVX or SQZ?

Summary

How does SQZ Biotechnologies compare to bioAffinity Technologies?

Do analysts rate BIAF or SQZ?

Which has more volatility & risk, BIAF or SQZ?

Which has higher earnings and valuation, BIAF or SQZ?

Is BIAF or SQZ more profitable?

Does the media favor BIAF or SQZ?

Do insiders and institutionals have more ownership in BIAF or SQZ?

Summary

How does SQZ Biotechnologies compare to Decoy Therapeutics?

Is SQZ or DCOY more profitable?

Do analysts recommend SQZ or DCOY?

Which has more risk & volatility, SQZ or DCOY?

Does the media refer more to SQZ or DCOY?

Do institutionals & insiders have more ownership in SQZ or DCOY?

Which has stronger earnings and valuation, SQZ or DCOY?

Summary

How does SQZ Biotechnologies compare to Propanc Biopharma?

Do analysts recommend PPCB or SQZ?

Is PPCB or SQZ more profitable?

Do institutionals and insiders have more ownership in PPCB or SQZ?

Which has stronger earnings and valuation, PPCB or SQZ?

Does the media favor PPCB or SQZ?

Which has more risk and volatility, PPCB or SQZ?

Summary

How does SQZ Biotechnologies compare to Genprex?

Do insiders & institutionals believe in SQZ or GNPX?

Do analysts rate SQZ or GNPX?

Is SQZ or GNPX more profitable?

Which has higher earnings & valuation, SQZ or GNPX?

Which has more risk and volatility, SQZ or GNPX?

Does the media refer more to SQZ or GNPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SQZ vs. The Competition

SQZ Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools